Hironori Koga

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

Takumi Kawaguchi, Takafumi Yoshida, Masaru Harada et al. · American Journal Of Pathology · 2004 · 536 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +8

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration

Yoshinori Fukui, Osamu Hashimoto, Terukazu Sanui et al. · Nature · 2001 · 446 citations

Life Sciences, Cell Biology, Immunology +11

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Expression of Cyclooxygenase–2 in Human Hepatocellular Carcinoma: Relevance to Tumor Dedifferentiation

Hironori Koga, Shotaro Sakisaka, Masahito Ohishi et al. · Hepatology · 1999 · 401 citations · Full text

Medicine, Cancer Biology, Oncology +13